Full-Time

Oncology Physicist

Posted on 11/24/2025

Akumin

Akumin

1,001-5,000 employees

Outsourced radiology and oncology services

No salary listed

Charleston, WV, USA

In Person

Up to 50% local travel.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Master's Degree required.
  • Certification in Therapeutic Radiological Physics required from: The American Board of Radiology or The American Board of Medical Physics or The Canadian College of Physics in Medicine
  • Experience as a radiation oncology medical physicist required, including clinical experience with linac calibrations and quality control, treatment planning system quality control and routine use, sealed isotope therapy and radiation safety, intensity-modulated radiation therapy planning and delivery, computer systems quality control, and medical physics program documentation.
  • Up to 50% local travel may be required.
  • COVID-19 vaccination may be a condition of employment.
  • Pre-employment background check and drug screen are required as a condition of employment.
Responsibilities
  • Ensures that all radiation oncology treatment, simulation machines and all sealed brachytherapy sources are correctly calibrated according to accepted protocols.
  • Assists with the implementation of a comprehensive program for quality control of the radiation-producing equipment to assure their constant acceptable performance for patient safety and treatment efficiency.
  • Assists the Chief Physicist with determining technical specifications for selection of new equipment, supervising installation of new equipment, performing acceptance testing upon completed installation, and measuring performance parameters to ensure the accurate clinical implementation of new equipment.
  • Implements and quality assurance of appropriate procedures for the planning and delivery of radiotherapy, including technical specifications/tolerances as well as the flow of procedures entailed in the process (including supervision and QC review of treatment plans and dose calculations).
  • Manages a comprehensive system for error prevention, including a method to learn from incidents (including “near misses”) with a focus on improving the process to minimize the risk of future incidents; ensures that clinical and physics procedures are subjected to a risk-informed assessment designed to minimize risks to patient and staff.
  • Serves as a resource for training and continuing education for all Radiation Oncology staff.

Akumin provides outsourced radiology and oncology services to hospitals, health systems, and physician groups across the United States through a network of fixed-site outpatient imaging centers and outpatient radiology and oncology services. It operates imaging centers and partners with healthcare facilities to offer diagnostic imaging, interpretation, and related outpatient services at scale across 47 states. Its nationwide focus on outsourced radiology and oncology allows hospitals to access imaging and cancer-care resources without maintaining all services in-house. The company aims to be a trusted partner for healthcare providers by delivering reliable, scalable imaging and cancer-care services that improve patient access to diagnostics and treatment.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plantation, Florida

Founded

1997

Simplify Jobs

Simplify's Take

What believers are saying

  • Stonepeak invests $154M for long-term growth capital.
  • Debt restructures to new notes due 2031 at 8.75-9.75%.
  • Private equity drives steady diagnostic imaging deals in 2025.

What critics are saying

  • RadNet acquisitions capture Akumin's MRI market share.
  • Stonepeak strips assets post-privatization in 18-36 months.
  • Alliance HealthCare poaches radiation oncology referrals.

What makes Akumin unique

  • Akumin AXIS Drop Trailer expands mobile imaging capabilities.
  • Relocatable MRI suites launched at RSNA meeting.
  • National network offers outpatient imaging and radiation therapy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Company News

Innovate Healthcare
Jan 5th, 2026
Akumin secures $154M investment and restructures debt to extend repayment timeline to 2031

Akumin Inc. has secured $154 million in new capital from Stonepeak, an alternative investment firm, to support long-term growth of its imaging and radiation oncology services. The company is also restructuring its debt with noteholders representing over 95% of its outstanding senior secured notes. Under the agreement, Akumin's existing debt will be exchanged for new senior secured notes due in 2031, carrying a 9.75% interest rate that can drop to 8.75% if certain credit targets are met. The company's revolving credit facility, with roughly $119 million outstanding, will convert into preferred equity or move to a lower-priority position. The restructuring follows Akumin's recent launch of new offerings at the Radiological Society of North America meeting, including its Axis Drop Trailer and relocatable MRI suites.

Cantech Letter
Oct 23rd, 2023
Akumin likely won’t get a better offer than Stonepeak, Clarus says

The deal from private equity firm Stonepeak to acquire Akumin likely won’t be topped, says Clarus Securities analyst Noel Atkinson.

PR Newswire
Oct 20th, 2023
Akumin Inc. Reaches Agreement With Stonepeak To Become A Private Company

Financial restructuring to fortify balance sheet and provide liquidity runway for next stage of growthApprovals received from key stakeholders across capital structure; transaction will be implemented through prepackaged court-supervised process; Expected to obtain court approval within the next 45 daysBusiness will continue to operate as usual without interruption; trade creditors, employees, and other partners expected to continue to be paid in ordinary coursePLANTATION, Fla., Oct. 20, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ: AKU) (TSX: AKU) announced today that it has reached an agreement with Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, and the Company's stakeholders on the terms of a financial restructuring that will substantially improve the Company's balance sheet and provide ample liquidity to position Akumin for future success. The contemplated transaction will result in Akumin no longer being publicly listed.To effect the transaction in a timely and efficient manner, the Company and certain of its subsidiaries will commence prepackaged chapter 11 cases in the Southern District of Texas. The Company expects to obtain court approval of the transaction within the next 45 days and complete the transaction after receiving certain regulatory approvals. Throughout the process, Akumin's operations are expected to continue as normal

INACTIVE